Department of Oral Medicine, Sedation and Maxillofacial Imaging, Hebrew University-Hadassah School of Dental Medicine, Jerusalem, Israel.
Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Jerusalem, Israel.
Support Care Cancer. 2021 Aug;29(8):4529-4534. doi: 10.1007/s00520-021-05997-1. Epub 2021 Jan 20.
To determine the immediate pain-relieving effect of photobiomodulation therapy (PBMt) in patients with oral ulcers of chronic graft-versus-host disease (cGVHD) refractory to first line therapy with topical corticosteroids.
This retrospective study included all patients who underwent PBMt for pain relief of refractory oral cGVHD lesions. PBMt was applied using an intraoral approach to all sites with mucosal lesions, using a 940 nm InGaAsP diode laser device, with the following parameters: pulsed modulation (duty cycle of 50%), power 0.7 W, illuminated spot size 7.1 cm, irradiance 98.6 mW/cm, and irradiation time 90 s per point. Pain was self-assessed using a 0-to-10 scale immediately before and after PBMt.
Data from eleven patients with a total of 56 PBMt sessions were analyzed. In 48 (85.7%) sessions, the patients reported less pain immediately after treatment, with a reduction of ≥ 50% of the initial pain level in 43 (76.8%) sessions. Mean pre- and post-treatment pain levels were 5.20 ±2.7 and 1.38 ±2.1, respectively (p < 0.001), i.e., a post-treatment reduction of 73.4% of the initial pain level. The benefits of the treatment remained for a mean of 6.50 ±5.4 days (range of 2 to 14 days). No adverse effects were reported.
PBMt seems to be a promising treatment modality for refractory oral cGVHD lesions as a rapid pain reliever with relatively long-lasting effects.
确定光生物调节疗法（PBMt）在一线治疗外用皮质类固醇治疗难治性口腔慢性移植物抗宿主病（cGVHD）患者疼痛中的即刻缓解效果。
本回顾性研究纳入了所有因难治性口腔 cGVHD 病变而接受 PBMt 缓解疼痛的患者。采用腔内方法对所有粘膜病变部位进行 PBMt，使用 940nm InGaAsP 二极管激光设备，以下参数：脉冲调制（占空比 50%），功率 0.7W，照射光斑大小 7.1cm，辐照度 98.6mW/cm，每个点照射时间 90s。治疗前和治疗后即刻，患者采用 0-10 分制自评疼痛程度。
分析了 11 例患者共 56 次 PBMt 治疗的数据。在 48 次（85.7%）治疗中，患者在治疗后立即报告疼痛减轻，43 次（76.8%）治疗中初始疼痛水平降低≥50%。治疗前和治疗后疼痛水平分别为 5.20±2.7 和 1.38±2.1（p<0.001），即初始疼痛水平降低 73.4%。治疗的获益平均持续 6.50±5.4 天（2-14 天）。未报告不良反应。
PBMt 似乎是一种很有前途的治疗方法，可作为一种快速缓解疼痛的方法，且具有相对持久的效果，用于治疗难治性口腔 cGVHD 病变。
